Despite staffing cuts at CMS, Organogenesis expects to manage through the challenges. Click here to read why I rate ORGO ...

Organogenesis (NASDAQ:ORGO) stock rallied 17% post-market on Thursday after the company released a Q4 earnings report and guidance that topped Street expectations. The biotech company reported a Q4 ...

Organogenesis has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.28, suggesting that its share price is ...

Organogenesis Holdings Inc. (NASDAQ:ORGO – Get Free Report) shares traded down 2.1% during mid-day trading on Friday .The company traded as low as $5.10 and last traded at $5.14. 220,836 shares ...

Learn more here. Operator Welcome, ladies and gentlemen, to the fourth quarter and fiscal year 2024 earnings conference call for Organogenesis Holdings, Inc. At this time, all participants have ...

Morgan Stanley raised the firm’s price target on Organogenesis (ORGO) to $6 from $4 and keeps an Equal Weight rating on the shares, citing a ...

Organogenesis Holdings shares soared after the company reported a profit in the fourth-quarter, while analysts had forecast a loss, and gave an upbeat outlook for the current year. Shares were ...

A negotiation for a tax stabilization agreement (TSA) between Smithfield and the biomedical company Organogenesis may be off to an unstable start, but the town and company seem ...

Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board for Organogenesis. “In 2025, we will continue to focus on our customers while we collaborate with policy and law makers ...

In a report released today, Patrick Wood from Morgan Stanley maintained a Hold rating on Organogenesis Holdings (ORGO – Research Report), with ...